Alnylam Pharmaceuticals Inc. (ALNY) reported a third-quarter loss of 22 cents per share, below the Zacks Consensus Estimate of 24 cents but wider than the year-ago loss of 7 cents. The higher loss in the quarter is attributable to higher stock based compensation and legal expenses.

Revenues for the quarter came in at $24.2 million as against $25.7 million in the year-ago quarter, down 5.8%. Research and development costs increased 5% to $23.2 million primarily because of increased costs for clinical and pre-clinical programs coupled with increased R&D headcount to support Alnylam’s alliances and development programs.    General and administrative expenses increased 56% to $10.7 million. The increase in general and administrative spend was primarily driven by higher professional service fees in association with business activities, primarily legal activities, coupled with increased stock based compensation expenses.   Alnylam exited the quarter with $453.5 million in cash, cash equivalents and marketable securities

...

Liberty Global Inc. (LBTYA) declared mixed financial results for the third quarter of 2009. Quarterly total revenue of $2.82 billion was an improvement of 7% year-over-year and also better than the Zacks Consensus Estimate of $2.75 billion. This was primarily due to the fabulous growth of Telnet and J:COM operations, which provides broadband services in Belgium and Japan respectively.  Quarterly GAAP net loss was $120.3 million or 45 cents per share compared to a net loss of $308.9 million or $1.01 in the prior-year quarter. However, third quarter net loss from continuing operation was 22 cents per share, above the Zacks Consensus estimate of a loss of 20 cents. Quarterly cost of operation was $1,059.2 million, up 5.5% year-over-year.  Selling, General and Administrative expense was $523.8 million, up 2.4% year-over-year. Third quarter operating income was $463.8 million, up 13.6% year-over-year. During the reported quarter, Liberty Global generated $691.4 ...

Osiris Therapeutics (OSIR) reported a net loss of 21 cents per share in the third quarter of 2009, well above the Zacks Consensus Estimate of a net income of 6 cents. However, net loss in the year ago period was higher at 63 cents, mainly due to lower revenues.  Revenues in the reported quarter increased to $10.6 million compared to $0.995 million for the same period of the prior year. Osiris generates revenues from collaborative agreements, research licenses, and government contracts.  Revenues in the reported quarter included the recognition of $10 million in revenue under the company’s agreement with Genzyme Corporation (GENZ) for the development and commercialization of Prochymal and Chondrogen.  Osiris earned $0.4 million from its collaborative agreement with the Juvenile Diabetes Research Foundation (JDRF) for the development of Prochymal for type I diabetes, $0.1 million from its contract with the Department of ...

Hologic, Inc. (HOLX) reported fourth-quarter earnings of 28 cents per share, which beat the Zacks Consensus Estimate of 26 cents. The company earned 30 cents in the year-ago quarter. For full fiscal 2009, the company earned $1.17 per share, which was above the Zacks Consensus Estimate by 2 cents but below the year-ago earnings by a cent.   Quarterly results   Revenues for the quarter were $402.8 million, in contrast to $442.5 million in the year-ago quarter thus representing a 8.9% decline. The decrease was primarily driven by the year-over-year decline in sales of Selenia systems, attributable primarily to the current economic environment, which resulted in delays and reductions in hospital capital spending and longer sales cycles. This overall decline was partially offset by growth in Diagnostics and Surgical product sales, increase in service and other revenues primarily related to increased installed base of Selenia full-field digital mammography ...

Cornerstone Therapeutics Inc. (CRTX) reported third-quarter earnings per share of 7 cents, compared to a profit of 49 cents in the year-ago quarter. The Zacks Consensus Estimate was pegged at 1 cent.   Net revenues for the quarter were up 12.1% to $23.1 million as against $20.6 million in the year-ago quarter. Revenues were boosted by the acquisition of a few products during the quarter. Sales for two of the company’s products fell due to increased competition. Hyomax sales fell 39 %, to $7.6 million, while the AlleRx Dose Pack product line witnessed a 42 % decrease to $3.5 million.   On the positive side, revenues from Spectracef sales increased $1.9 million for the reported quarter primarily due to the enhanced promotion of the drug by Cornerstone’s sales force to targeted physicians.   Zyflo CR and Zyflo revenues came in at $5 million for the reported quarter.  Curosurf ...

Raser Technologies Inc. (RZ) reported a loss per share of 5 cents, less than the Zacks Consensus loss per share estimate of 13 cents in the third quarter of fiscal 2009. Also, net loss of 5 cents per share is less than half compared to the year-ago loss of 13 cents per share.  The improvement in earnings came despite shares outstanding increasing to 74.9 million in the reported quarter from 57.8 million in the year-ago quarter. The revenue front, the company reported revenue totaling $0.8 million as compared to $0.03 million during the year-ago quarter. The improvement was due to the initiation of a revenue stream from selling electricity generated by its geothermal power plant to the city of Anaheim.  During the reported quarter, the company generated and sold approximately 9,819 MW hours of electricity. Similarly in the reported quarter, cost of sales rose to $2.9 million ...

Satellite TV major Dish Network Corp.’s (DISH) third-quarter earnings slipped 12.3% on higher subscriber-related costs and litigation expenses associated with TiVo Inc. (TIVO). The company reported earnings of $80.6 million, or 18 cents per share, compared to $91.9 million, or 20 cents in the year-ago quarter and well behind the Zacks Consensus Estimate of 43 cents. The Englewood, Colorado-based company said total revenue declined 1.5% to $2.89 billion, from $2.94 billion in the year-ago period. The decrease was caused by a 0.8% contraction in subscriber related revenue to $2.86 billion as average monthly revenue per subscriber (ARPU) reduced by $0.31 to $69.51. The lower ARPU was the result of discounts on programming to new subscribers, retention efforts and reduced premium movie revenue, partially offset by price increases on popular programming packages, changes in the sales mix towards high-definition (HD) packages and advanced hardware offerings. Equipment ...

Edison International's (EIX) adjusted EPS of $1.09 in the third quarter of fiscal 2009 pushed past the Zacks Consensus Estimate of $1.05 by 4 cents. However, adjusted EPS for the quarter fell short of the year-ago $1.46 EPS.

On a GAAP basis, the company reported quarterly EPS of $1.23, compared to $1.33 in the year-ago quarter. The discrepancy between GAAP and adjusted EPS were due to non-cash accounting benefit from the final regulatory approval to transfer its Mountainview power plant to utility rate base.

Edison's revenue fell 14.7% year-over-year to $3.7 billion from $4.3 billion. The downside was more prominent in electric utility revenue (83.7% of total revenues), which decreased 11.6% year-over-year. Competitive power generation revenues fell 27.2% to $592 million. Financial services and other revenues were only $7 million in the reported quarter from $14 million in the year-ago quarter.

Southern California Edison's (SCE) GAAP EPS in the reported quarter

...

American Medical Systems Holdings, Inc. (AMMD) reported strong fiscal third quarter results. For the quarter, earnings per share was 27 cents, beating the Zacks Consensus Estimate of 20 cents and the year-ago earnings of 18 cents. Earnings per share for the reported quarter were also ahead of the company’s previous guidance of 17 to 21 cents.   Sales   Total sales for the quarter increased 4.9% year over year to $123.2 million. Excluding an unfavorable foreign currency translation (FX), net sales increased 6.7% year over year. On a geographic basis, U.S. sales accounted for roughly 75% of total sales and increased 9.2% year over year. International sales declined 6.1% year over year.   In terms of business segments: Men’s health revenues increased 6.6% year over year to $54.7 million. Growth was primarily due to higher sales of the erectile restoration system.   Women’s health revenues increased 4% year over

...

Teva Pharmaceutical Industries Ltd. (TEVA) reported earnings of 89 cents in the third quarter of 2009, up 16% from the year-ago period and a cent above the Zacks Consensus Estimate. Strong sales of Copaxone and in the respiratory business helped drive earnings in the reported quarter. Net sales increased 25% to $3.55 billion, with the Barr acquisition contributing to sales across different geographical segments. The strengthening U.S. dollar adversely impacted net sales by $160 million or 6%. Revenue performance across key business segments was mixed. While the Pharmaceuticals Sales segment posted growth of 27% with revenues coming in at $3.4 billion, the active pharmaceutical ingredients (API) segment reported an 8% decline in growth with sales coming in at $136 million. Pharmaceutical segment sales were driven by strong performances in the North American, European and International segments. The launch of generic versions of Ortho Tri-Cyclen Lo ...